Mantle cell lymphoma is a kind of disease that affects the lymphatic system (which is a part of immune system). Mantle cell lymphoma is life-threatening, slow-growing cancers which involves accumulation of cancerous B-cells at mantle zone in the lymph node. Mantle cell lymphoma can be symptomatized by night sweats, fever, weight loss and fatigue. Intestinal obstruction, multiple intestinal polyps, high blood count, and intussusception are observed in patients with mantle cell carcinoma. Somatic DNA damage is observed as the major cause of mantle cell lymphoma. The disease can be diagnosed by lymph node biopsy, bone marrow biopsy, and flow cytometry. Immunohistochemistry, cytogenetic analysis, immunophenotyping, and fluorescence in situ hybridization (FISH) are the tests to study the cancer cells. Millennium Pharmaceuticals, Inc. is in the process of developing ixazomib as a proteasome inhibitor for the treatment of mantle cell lymphoma. Merck Sharp & Dohme Corp. is in the process of developing ibrutinib as a bruton's tyrosine kinase inhibitor for the treatment of mantle cell lymphoma. Some of the companies having the pipeline of mantle cell lymphoma include Millennium Pharmaceuticals, Inc., Kite Pharma, Inc., Merck Sharp & Dohme Corp., and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.